Log in

NASDAQ:CELGCelgene Stock Price, Forecast & News

$108.24
0.00 (0.00 %)
(As of 06/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$108.24
Now: $108.24
$108.24
50-Day Range
$108.24
MA: $108.24
$108.24
52-Week Range
$58.59
Now: $108.24
$110.70
VolumeN/A
Average Volume6.77 million shs
Market Capitalization$77.04 billion
P/E Ratio14.22
Dividend YieldN/A
Beta1.41
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; and EXSCIENTIA LTD. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Read More
Celgene logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 3.1 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.75 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CELG
CUSIP15102010
Phone908-673-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.28 billion
Cash Flow$8.88 per share
Book Value$16.98 per share

Profitability

Net Income$4.05 billion

Miscellaneous

Employees8,852
Market Cap$77.04 billion
Next Earnings DateN/A
OptionableOptionable

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Celgene (NASDAQ:CELG) Frequently Asked Questions

How has Celgene's stock been impacted by COVID-19 (Coronavirus)?

Celgene's stock was trading at $108.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CELG stock has increased by 0.0% and is now trading at $108.24. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Celgene?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celgene in the last year. There are currently 6 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Celgene.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) released its quarterly earnings data on Thursday, October, 31st. The biopharmaceutical company reported $2.99 EPS for the quarter, topping the consensus estimate of $2.70 by $0.29. The biopharmaceutical company earned $4.52 billion during the quarter, compared to analysts' expectations of $4.39 billion. Celgene had a return on equity of 78.15% and a net margin of 34.63%. The firm's quarterly revenue was up 16.1% on a year-over-year basis. During the same period last year, the company earned $2.29 earnings per share. View Celgene's earnings history.

When did Celgene's stock split? How did Celgene's stock split work?

Shares of Celgene split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly issued shares were distributed to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

What price target have analysts set for CELG?

6 Wall Street analysts have issued 12 month target prices for Celgene's shares. Their forecasts range from $100.00 to $115.00. On average, they anticipate Celgene's stock price to reach $105.60 in the next twelve months. This suggests that the stock has a possible downside of 2.4%. View analysts' price targets for Celgene.

Has Celgene been receiving favorable news coverage?

News headlines about CELG stock have been trending very negative on Thursday, InfoTrie reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Celgene earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutCelgene.

Who are some of Celgene's key competitors?

What other stocks do shareholders of Celgene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celgene investors own include Akorn (AKRX), Gilead Sciences (GILD), Skechers USA (SKX), NVIDIA (NVDA), Bank of America (BAC), Integrated Device Technology (IDTI), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU) and Intel (INTC).

Who are Celgene's key executives?

Celgene's management team includes the following people:
  • Mr. Mark J. Alles, Chairman & CEO (Age 60)
  • Mr. David V. Elkins, Exec. VP & CFO (Age 50)
  • Mr. Peter N. Kellogg, Exec. VP & Chief Corp. Strategy Officer (Age 63)
  • Dr. S. J. Rupert Vessey MA, BM BCh, FRCP, DPhil, Pres of Research & Early Devel. (Age 54)
  • Dr. Alise Reicin M.D., Pres of Global Clinical Devel. (Age 58)

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

Who are Celgene's major shareholders?

Celgene's stock is owned by a variety of institutional and retail investors. Top institutional investors include Central Bank & Trust Co. (0.01%), Osborn Williams & Donohoe LLC (0.01%), Osborn Williams & Donohoe LLC (0.01%), Thomasville National Bank (0.01%), Headinvest LLC (0.00%) and Perennial Advisors LLC (0.00%). Company insiders that own Celgene stock include Ernest Mario, James J Loughlin, John H Weiland, Michael D Casey and Terrie Curran. View institutional ownership trends for Celgene.

Which institutional investors are buying Celgene stock?

CELG stock was purchased by a variety of institutional investors in the last quarter, including Central Bank & Trust Co., Osborn Williams & Donohoe LLC, Osborn Williams & Donohoe LLC, Thomasville National Bank, Headinvest LLC, and Perennial Advisors LLC. Company insiders that have bought Celgene stock in the last two years include Ernest Mario, and John H Weiland. View insider buying and selling activity for Celgene.

How do I buy shares of Celgene?

Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Celgene's stock price today?

One share of CELG stock can currently be purchased for approximately $108.24.

How big of a company is Celgene?

Celgene has a market capitalization of $77.04 billion and generates $15.28 billion in revenue each year. The biopharmaceutical company earns $4.05 billion in net income (profit) each year or $7.61 on an earnings per share basis. Celgene employs 8,852 workers across the globe.

What is Celgene's official website?

The official website for Celgene is www.celgene.com.

How can I contact Celgene?

Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.